Evidence map›Paper›PMID 38740934›Full record

ArticleNature nanotechnology2024

Nanoparticles for inducing Gaucher disease-like damage in cancer cells.

Chunyan Yue, Wenjing Lu, Shuxin Fan, Zhusheng Huang, Jiaying Yang, Hong Dong, Xiaojun Zhang, Yuxin Shang, Wenjia Lai, Dandan Li and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature nanotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Chunyan Yue *State Key Laboratory of Pharmaceutical Biotechnology, Medical School, Nanjing University, Nanjing, China.ORCID http://orcid.org/0000-0002-8045-5819
Wenjing Lu *State Key Laboratory of Pharmaceutical Biotechnology, Medical School, Nanjing University, Nanjing, China.
Shuxin Fan *State Key Laboratory of Pharmaceutical Biotechnology, Medical School, Nanjing University, Nanjing, China.
Zhusheng HuangState Key Laboratory of Pharmaceutical Biotechnology, Medical School, Nanjing University, Nanjing, China.ORCID http://orcid.org/0000-0002-0676-9799
Jiaying YangState Key Laboratory of Pharmaceutical Biotechnology, Medical School, Nanjing University, Nanjing, China.
Hong DongState Key Laboratory of Pharmaceutical Biotechnology, Medical School, Nanjing University, Nanjing, China.
Xiaojun ZhangState Key Laboratory of Pharmaceutical Biotechnology, Medical School, Nanjing University, Nanjing, China.
Yuxin ShangState Key Laboratory of Pharmaceutical Biotechnology, Medical School, Nanjing University, Nanjing, China.
Wenjia LaiCAS Key Laboratory of Standardization and Measurement for Nanotechnology, National Center for Nanoscience and Technology, Beijing, China.
Dandan LiState Key Laboratory of Pharmaceutical Biotechnology, Medical School, Nanjing University, Nanjing, China.
Tiejun DongState Key Laboratory of Pharmaceutical Biotechnology, Medical School, Nanjing University, Nanjing, China.ORCID http://orcid.org/0000-0003-3434-3370
Ahu YuanState Key Laboratory of Pharmaceutical Biotechnology, Medical School, Nanjing University, Nanjing, China.
Jinhui WuState Key Laboratory of Pharmaceutical Biotechnology, Medical School, Nanjing University, Nanjing, China.ORCID http://orcid.org/0000-0001-8809-1290
Lifeng KangSchool of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0002-1676-7607
Yiqiao HuState Key Laboratory of Pharmaceutical Biotechnology, Medical School, Nanjing University, Nanjing, China. huyiqiao@nju.edu.cn.ORCID http://orcid.org/0000-0002-3656-7143

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82204293
6 · The paper itself

Abstract

Nutrient avidity is one of the most distinctive features of tumours. However, nutrient deprivation has yielded limited clinical benefits. In Gaucher disease, an inherited metabolic disorder, cells produce cholesteryl-glucoside which accumulates in lysosomes and causes cell damage. Here we develop a nanoparticle (AbCholB) to emulate natural-lipoprotein-carried cholesterol and initiate Gaucher disease-like damage in cancer cells. AbCholB is composed of a phenylboronic-acid-modified cholesterol (CholB) and albumin. Cancer cells uptake the nanoparticles into lysosomes, where CholB reacts with glucose and generates a cholesteryl-glucoside-like structure that resists degradation and aggregates into microscale crystals, causing Gaucher disease-like damage in a glucose-dependent manner. In addition, the nutrient-sensing function of mTOR is suppressed. It is observed that normal cells escape severe damage due to their inferior ability to compete for nutrients compared with cancer cells. This work provides a bioinspired strategy to selectively impede the metabolic action of cancer cells by taking advantage of their nutrient avidity.

Indexed as

Gaucher DiseaseLysosomesNanoparticlesAnimalsBoronic AcidsCell Line, TumorCholesterolGlucoseHumansNeoplasmsTOR Serine-Threonine Kinasesbenzeneboronic acidBoronic AcidsCholesterolGlucoseTOR Serine-Threonine Kinases

Identifiers

PMID38740934

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.